Novo Nordisk Sees Chance of U.S. Tresiba Launch Before Rivals

21.03.2014 - Novo Nordisk should still be able to introduce its long-acting insulin Tresiba on the U.S. market before rival products, despite being hit by a delay, the CEO of the Danish...